MedPath
Found 4 clinical trials|View Analysis
Sort by:

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Phase 2
Recruiting
Conditions
Li-Fraumeni Syndrome
p53 Mutations
Pediatric Cancer
Interventions
First Posted Date
2023-10-18
Last Posted Date
2024-01-03
Lead Sponsor
Yang Li
Target Recruit Count
50
Registration Number
NCT06088030
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

Phase 2
Conditions
Myelodysplastic Syndromes
Myeloid Malignancy
Sodium Stibogluconate
Temperature-Sensitive p53 Mutation
P53 Mutation
Acute Myeloid Leukemia
Interventions
First Posted Date
2021-05-28
Last Posted Date
2021-06-09
Lead Sponsor
First Affiliated Hospital of Jinan University
Target Recruit Count
5
Registration Number
NCT04906031
Locations
🇨🇳

First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China

Arsenic Trioxide for Structural p53 Mutations

Phase 2
Conditions
Refractory Cancer
p53 Mutations
Intractable Cancer
Arsenic Trioxide
Interventions
First Posted Date
2021-01-05
Last Posted Date
2021-01-06
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
30
Registration Number
NCT04695223
Locations
🇨🇳

Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai, China

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Phase 2
Conditions
Acute Myeloid Leukemia
P53 Mutation
Interventions
First Posted Date
2017-12-22
Last Posted Date
2018-01-04
Lead Sponsor
Li Junmin
Target Recruit Count
100
Registration Number
NCT03381781
Locations
🇨🇳

Shanghai Institute of Hematology, Shanghai, China

🇨🇳

Ruijin Hospital North, Shanghai, China

🇨🇳

Ruijin Hospital, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath